Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality ImprovementRelease Date:Quality Improvement Oncology Kazakhstan Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer CareEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology China, France, Germany, Italy, Japan, Spain, Turkey, United Kingdom Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Title Grant Type Focus Area Country Application Due Date Implementation of Telemedicine in Inflammatory Conditions: A Quality Improvement RFPRelease Date:Quality Improvement Inflammation & Immunology Canada, USA ADVANCE: Global Awards for Advancing Chronic Pain ResearchResearch Internal Medicine All Improving Disparities in Ulcerative Colitis Health Care in Post COVID-19 EraRelease Date:Quality Improvement Inflammation & Immunology United Kingdom New Guidelines for Immuno-therapy in Urothelial Carcinoma (UC)Release Date:Partner: Merck KGaA Darmstadt, Germany and EMD SeronoEducation Oncology France, Germany, Italy, Spain, USA, United Kingdom Emerging Mechanisms of Action in the Treatment of Moderate-to-Severe Alopecia AreataRelease Date:Education Inflammation & Immunology USA PARP-inhibitor Combination Treatments in Prostate CancerRelease Date:Education Oncology All Remote Mentoring Programs in RCCRelease Date:Education Oncology USA Quality of Care Improvement in Metastatic Breast Cancer Patients (Europe)Release Date:Partner: The Sharing Progress in Cancer Care (SPCC)Quality Improvement Oncology All Metastatic Breast Cancer Patient Education: Navigating Treatment & Decision MakingRelease Date:Education Oncology Canada, USA Identifying and Diagnosing polyarticular Juvenile Idiopathic Arthritis (pJIA)Release Date:Education Inflammation & Immunology Canada, USA NSCLC Oncogene Driver Considerations in Testing & TreatmentRelease Date:Education Oncology USA Unmet Need and Burden of Disease in Moderate-to-Severe Alopecia AreataRelease Date:Education Inflammation & Immunology France, Germany